Focus
CRISPR-Cas9
FDA Approves Gene Therapy for Inherited Blood Disorder
The treatment for Beta-Thalassemia is expected to cost $2.2 million and will be available in the United States this year.
FDA Document Raises Concerns Over a New Gene Editing Therapy
A cutting-edge cure or CRISPR catastrophe? That’s the question facing regulators.
GMO 2.0: A New Kind of Modified Food Escapes Regulation
A new kind of GMO is going by different names, and largely escaping regulation as it enters grocery stores.
